All In Biotech

Free tool

FAERS Monitor: Folotyn

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 022468 or its brand name (Folotyn, Pralatrexate). Reports on generic versions are filed under their own applications.

Reports

650

Serious

603

93% of reports

Hospitalization

259

Death reported

164

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • malignant neoplasm progression118
  • stomatitis103
  • disease progression71
  • mucosal inflammation64
  • platelet count decreased57
  • pyrexia51
  • anaemia49
  • neutrophil count decreased42
  • drug ineffective41
  • febrile neutropenia39
  • neutropenia34
  • off label use33
  • thrombocytopenia33
  • death32
  • diarrhoea25

Reports by year received

View as table
YearReports
201031
201133
201238
201337
201415
201524
201629
201724
201846
201943
202062
2021105
202259
202335
202424
202533
202612

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,509 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
mucosal inflammationSignal6479.362.84,864
stomatitisSignal10355.046.15,418
malignant neoplasm progressionSignal11837.331.74,151
neutrophil count decreasedSignal4233.424.91,288
disease progressionSignal7119.415.61,229
febrile neutropeniaSignal3919.014.0650
platelet count decreasedSignal5717.313.5864
thrombocytopeniaSignal339.66.8245
anaemiaSignal498.36.4311
neutropeniaSignal348.15.8206
pyrexiaSignal514.83.7151
diarrhoea251.30.91
off label use331.20.91
death321.20.91
drug ineffective411.00.70

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.